Leisha A. Emens, MD, PhD, professor of medicine, Hematology/Oncology, co-leader, Hillman Cancer Immunology and Immunotherapy Program, director, Translational Immunotherapy for the Women’s Cancer Research Center, UPMC Hillman Cancer Center, discusses a potential future with immunotherapy in ovarian cancer.

It is understood that moving immunotherapy to the frontline setting elicits greater efficacy for women with ovarian cancer, explains Emens. Additionally, PD-L1—positive patients derive a greater benefit from the agents currently available in this space.

As such, the future of immunotherapy in ovarian cancer requires a good signal of activity with available agents. Clinical trials that incorporate biomarker analyses may allow investigators to better predict which patients are more likely to respond to this modality of treatment, concludes Emens.